Pharmaceutical Executive
In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses-pharma-related, of course-to be published on our website in late August.
The "tawny streaks and shades" of summer sunlight, as Walt Whitman put it, have a mellowing effect; leisurely hours spent in scenic locales, on vacation or just out on the weekend, provide an opportunity for unhurried thought and easy reflection ("heat dome" notwithstanding). In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses—pharma-related, of course—to be published on our website in late August. Send those jottings from the post-conference tarmac, the hotel bar, or the family vacation to bcomer@advanstar.com, if you are so inclined. Our pseudonymous colleague Stix Daley has contributed one of his recent scribblings to kick things off. Summer will be gone soon, so take it slow while you can, and enjoy.
Pharmacopoeticsby Stix Daley
Longitudinal studies on red meat with clever endpoints.
Freedom to choose cigarettes and their adverse events.
By QALY, I develop the best immunity
I mean by golly.
Policy and people need most toexpire—
in their due time of course.
Meantime I’ve mislaid the data
that I
well I guess that I
ought to report.
Fee-for-service reimagined as
Hippocratical aphorism.
A cunning caduceus loosed
in the waiting room.
To Asclepius’s chagrin.
Even our immune systems are uniting
in mutiny
Coffee cup copays a fair market value
or just an encephalographic
image problem.
Commodities traders and doctors
know better.
Or regular Tories.
I mean no better.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.